Cargando…

Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate

The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low molecular weight heparins (LMWH) and vitamin K antagonists, are safe and effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendoff, D, Perka, C, Fritsche, H.M, Gehrke, T, Hube, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263520/
https://www.ncbi.nlm.nih.gov/pubmed/22276081
http://dx.doi.org/10.2174/1874325001105010395
_version_ 1782221876346486784
author Kendoff, D
Perka, C
Fritsche, H.M
Gehrke, T
Hube, R
author_facet Kendoff, D
Perka, C
Fritsche, H.M
Gehrke, T
Hube, R
author_sort Kendoff, D
collection PubMed
description The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low molecular weight heparins (LMWH) and vitamin K antagonists, are safe and effective their use can be problematic. Therefore, there is a need for alternative anticoagulants that are as safe and effective as conventional agents, but are more convenient and easier to use. Dabigatran etexilate, a direct thrombin inhibitor, is one such anticoagulant. For VTE prevention following major orthopaedic surgery, dabigatran etexilate shows similar efficacy and safety to the LMWH enoxaparin, and is approved for use in more than 75 countries, including Europe and Canada. Here, we summarize and discuss the experiences of four German clinics that have recently introduced dabigatran etexilate into clinical practice. Overall, dabigatran etexilate was well received by patients, surgeons and nurses, and compared favourably with enoxaparin. Staff appreciated the oral, single-dose administration of dabigatran etexilate. Patient satisfaction was high, especially in those individuals who had previously used LMWHs. In this review, we also address a number of questions that were asked by patients or staff; this will be of relevance to orthopaedic surgeons and nurses. We conclude that, in these four German clinics, dabigatran etexilate offered an effective oral alternative to existing thromboprophylactic agents in patients undergoing major orthopaedic surgery.
format Online
Article
Text
id pubmed-3263520
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-32635202012-01-24 Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate Kendoff, D Perka, C Fritsche, H.M Gehrke, T Hube, R Open Orthop J Article The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low molecular weight heparins (LMWH) and vitamin K antagonists, are safe and effective their use can be problematic. Therefore, there is a need for alternative anticoagulants that are as safe and effective as conventional agents, but are more convenient and easier to use. Dabigatran etexilate, a direct thrombin inhibitor, is one such anticoagulant. For VTE prevention following major orthopaedic surgery, dabigatran etexilate shows similar efficacy and safety to the LMWH enoxaparin, and is approved for use in more than 75 countries, including Europe and Canada. Here, we summarize and discuss the experiences of four German clinics that have recently introduced dabigatran etexilate into clinical practice. Overall, dabigatran etexilate was well received by patients, surgeons and nurses, and compared favourably with enoxaparin. Staff appreciated the oral, single-dose administration of dabigatran etexilate. Patient satisfaction was high, especially in those individuals who had previously used LMWHs. In this review, we also address a number of questions that were asked by patients or staff; this will be of relevance to orthopaedic surgeons and nurses. We conclude that, in these four German clinics, dabigatran etexilate offered an effective oral alternative to existing thromboprophylactic agents in patients undergoing major orthopaedic surgery. Bentham Open 2011-12-30 /pmc/articles/PMC3263520/ /pubmed/22276081 http://dx.doi.org/10.2174/1874325001105010395 Text en © Kendoff et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Kendoff, D
Perka, C
Fritsche, H.M
Gehrke, T
Hube, R
Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title_full Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title_fullStr Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title_full_unstemmed Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title_short Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
title_sort oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263520/
https://www.ncbi.nlm.nih.gov/pubmed/22276081
http://dx.doi.org/10.2174/1874325001105010395
work_keys_str_mv AT kendoffd oralthromboprophylaxisfollowingtotalhiporkneereplacementreviewandmulticentreexperiencewithdabigatranetexilate
AT perkac oralthromboprophylaxisfollowingtotalhiporkneereplacementreviewandmulticentreexperiencewithdabigatranetexilate
AT fritschehm oralthromboprophylaxisfollowingtotalhiporkneereplacementreviewandmulticentreexperiencewithdabigatranetexilate
AT gehrket oralthromboprophylaxisfollowingtotalhiporkneereplacementreviewandmulticentreexperiencewithdabigatranetexilate
AT huber oralthromboprophylaxisfollowingtotalhiporkneereplacementreviewandmulticentreexperiencewithdabigatranetexilate